Related references
Note: Only part of the references are listed.The evolving role of immunotherapy in prostate cancer
W. R. Gerritsen
ANNALS OF ONCOLOGY (2012)
Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy
Nicolo Rigamonti et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Treatment Decisions for Metastatic Castration-resistant Prostate Cancer Progressing After Docetaxel Chemotherapy: The Role of Cabazitaxel in the Continuumof Care
Axel Heidenreich et al.
EUROPEAN UROLOGY (2012)
Novel Agents and Approaches for Advanced Renal Cell Carcinoma
Robert Figlin et al.
JOURNAL OF UROLOGY (2012)
Unmasking the immune recognition of prostate cancer with CTLA4 blockade
Serena S. Kwek et al.
NATURE REVIEWS CANCER (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
Robert E. Hunger et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Paal Fr. Brunsvig et al.
CLINICAL CANCER RESEARCH (2011)
Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
Susanne M. Rittig et al.
MOLECULAR THERAPY (2011)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Immunogenicity of the hTERT540-548 peptide in cancer
Lynn Wenandy et al.
CLINICAL CANCER RESEARCH (2008)
Telomerase as a universal tumor antigen for cancer vaccines
Gregory L. Beatty et al.
EXPERT REVIEW OF VACCINES (2008)
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma - A clinical, phase 1/2 trial
Annika Berntsen et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Safety and immunogenicity of two influenza virus subunit vaccines, with or without MF59 adjuvant, administered to human immunodeficiency virus type 1-seropositive and -seronegative adults
P. Durando et al.
CLINICAL AND VACCINE IMMUNOLOGY (2008)
Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming
Danila Valmori et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Four functionally distinct populations of human effector-memory CD8+ T lymphocytes
Pedro Romero et al.
JOURNAL OF IMMUNOLOGY (2007)
Telomerase immunity from bench to bedside: round one
Xochtil Cortez-Gonzalez et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2007)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Paal F. Brunsvig et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Topical imiquimod is a potent adjuvant to a weakly-immunogenic protein prototype vaccine
D Johnston et al.
VACCINE (2006)
First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer - Does sequence matter?
J Michels et al.
CANCER (2006)
Frequency of telomerase-specific CD8+ T lymphocytes in patients with cancer
G Filaci et al.
BLOOD (2006)
A novel assay for assessment of HIV-specific cytotoxicity by multiparameter flow cytometry
K Godoy-Ramirez et al.
CYTOMETRY PART A (2005)
Human CD4+ T cells are predominantly distributed among six phenotypically and functionally distinct subsets
E Amyes et al.
JOURNAL OF IMMUNOLOGY (2005)
Artificial antigen-presenting cells transduced with telomerase efficiently expand epitope-specific, human leukocyte antigen-restricted cytotoxic T cells
J Dupont et al.
CANCER RESEARCH (2005)
Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes
RH Vonderheide et al.
CLINICAL CANCER RESEARCH (2004)
Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase
MR Parkhurst et al.
CLINICAL CANCER RESEARCH (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
Telomeres, telomerase and cancer: an up-date
K Dhaene et al.
VIRCHOWS ARCHIV-AN INTERNATIONAL JOURNAL OF PATHOLOGY (2000)
Cytotoxic T cell immunity against telomerase reverse transcriptase in humans
B Minev et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
